This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter revenue up 18.7%, profit after tax up 1.4%; leadership changes
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone Sep 2026 quarter: revenue rose 18.7% to Rs 2,639.08 million from Rs 2,223.98 million a year earlier; profit after tax rose 1.4% to Rs 180.52 million from Rs 178.00 million. Operating earnings margin fell to 11.1% from 12.8%. Auditor review found no material misstatement. Ashok Windlass resigned as whole-time director and will become Founder President pending shareholder approval; Hitesh Windlass is now Chairman and Managing Director.
Revenue growth is positive, but nearly flat profit and a lower operating earnings margin may limit gains. Leadership succession appears orderly.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹263.9 Cr | ₹222.4 Cr | +18.7% |
| Operating profit | ₹19.44 Cr | ₹19.94 Cr | −2.5% |
| Profit after tax | ₹18.05 Cr | ₹17.80 Cr | +1.4% |
| EBITDA margin | 11.1% | 12.8% | −1.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.